Faruqi & Faruqi Issues Reminder About Baxter Class Action Lawsuit and Plaintiff Deadline

Baxter International Class Action Lawsuit Notification

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities, is actively investigating potential claims on behalf of investors against Baxter International Inc., commonly known as Baxter. This investigation pertains to a federal securities class action lawsuit that has been filed against the company. If you purchased or acquired Baxter securities between February 23, 2022, and October 29, 2025, this alert is crucial for you.

Important Deadlines and Legal Rights

Investors are reminded of the impending deadline of December 15, 2025, for those wishing to be appointed as lead plaintiff in this class action suit. The lead plaintiff plays a vital role, representing the class in the litigation against Baxter. It’s essential for investors who have suffered losses to consider this opportunity to influence the proceedings effectively.

Allegations Against Baxter International

The lawsuit alleges significant violations of federal securities laws by Baxter and its executives. It accuses them of making misleading statements about the safety and functionality of their Novum LVP (Large Volume Pump) device. The complaint asserts that:

1. The Novum LVP encountered structural flaws leading to severe malfunctions including incorrect fluid delivery, posing serious health risks such as injury or even death.
2. Baxter was already aware of numerous instances of device failures, injuries, and fatalities related to these defects but failed to make meaningful disclosures to their investors and the public.
3. Baxter inadequately addressed these safety concerns through customer alerts, which were insufficient to remedy the persistent design issues that jeopardized patient safety.
4. Consequently, there was a significant risk that Baxter customers would be compelled to withdraw existing Novum LVPs from use, leading to a complete halt of all new sales and installations of the affected pumps.

5. As a result of these issues, Baxter’s assertions regarding the product’s safety, effectiveness, and market prospects were deemed materially false or misleading.

This ongoing case has already seen significant repercussions for Baxter; on July 31, 2025, the company announced a voluntary halt on shipments and installations of the Novum LVP. Following this announcement, Baxter's stock tragically fell by 22.4%, resulting in a closing price of $21.76.

Your Right to Participate

Each potential member of the class can choose to either move to serve as lead plaintiff through their own legal counsel or remain an absent class member. Your potential recovery will hinge upon the decision you make regarding your involvement in the case. It’s vital to note that your ability to benefit from a successful outcome remains intact, irrespective of whether you choose to become a lead plaintiff or not.

Call for Information

Faruqi & Faruqi actively encourages anyone with relevant information about Baxter’s practices—be it whistleblowers, former employees, or shareholders—to come forward. Such contributions could critically assist the ongoing investigation and strengthen the case against Baxter.

Next Steps for Interested Investors

To learn more about the ongoing class action lawsuit against Baxter International, visit the Faruqi & Faruqi website for detailed information. Investors can also reach out directly to Faruqi & Faruqi's partner, Josh Wilson, who can provide insights and facilitate further discussions about your legal rights. He can be contacted at 877-247-4292 or via his extension 212-983-9330 (Ext. 1310).

This alert highlights the critical nature of the ongoing legal situation concerning Baxter International and the significant risks that investors may face. Staying informed and engaged is paramount for those who have invested in the company during the affected period.